Nexstim Plc - exercise of warrants pursuant to the financing arrangement announced on 21 July 2016

Company announcement, Helsinki, 31 May 2017, at 1:00 pm

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or the "Company"), a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic and diagnostic applications, announces that it has received a warrant exercise notice pursuant to the financing arrangement announced on 21 July 2016. Bracknor subscribes for a total of 3,448,117  new shares with a subscription price of EUR 0.1411 per share in accordance with the terms and conditions of the warrants. The aggregate subscription price for the shares subscribed for with warrants amounts therefore to EUR 486,529.31. The new shares will be listed approximately on 6 June 2017. After the exercise of the warrants the total number of registered shares in the Company will be 84,578,450.

NEXSTIM PLC
Martin Jamieson, Chairman and CEO

Further information is available on the websitewww.nexstim.com or by contacting:

Nexstim                                                             +447715163942
Martin Jamieson, Chairman and CEO martin.jamieson@nexstim.com
                                                                                                                                                                                                        
UB Securities Oy (Certified Adviser)        +358 (0)9 2538 0246

Citigate Dewe Rogerson                       +44 (0)207 2821066
Katja Stout                                      katja.stout@citigatedr.co.uk

About Nexstim Plc
Nexstim is a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic (NBT® system) and diagnostic (NBS system) applications. Nexstim's NBS system is the only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for the pre-surgical mapping of the speech and motor cortices of the brain.

Based on the same technology platform, the Company has developed the Navigated Brain Therapy (NBT®) which is CE marked for the treatment of stroke, major depression and chronic neuropathic pain. The NBT® system is currently in a supplemental Phase III study, E-FIT trial, which will recruit 60 patients. The trial is expected to complete in Q2 2018, allowing Nexstim to file for FDA clearance. FDA clearance would allow Nexstim to start marketing and selling its NBT® system for stroke rehabilitation in the USA.

Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com

Nexstim Plc - exercise of warrants

--
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nexstim Oyj via Globenewswire